The Swiss-headquartered CDMO is acquiring a commercial-scale site in Wilmington, Delaware and a clinical active pharmaceutical ingredient facility in Athens, Georgia.
Manufactured under cGMP conditions, the additions include low-endotoxin and enzyme-free formulations for laboratories and manufacturing use, the company said.
